I did not listen to the call. Apparently, those w
Post# of 148281
If that is the case, then I am extraordinarily disappointed, particularly in light of the following:
"CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company" , a late-stage biotechnology company announced today it has provided its Top-line Report from its recently completed, randomized, double-blind, Phase 2 trial for COVID-19 patients with mild-to-moderate symptoms to the U.S. Food and Drug Administration (FDA), and requested emergency use approval ."
https://www.cytodyn.com/newsroom/press-releas...ts-phase-2